US: FTC Chairwoman Ramirez testifies before Senate Judiciary Subcommittee on antitrust
Testifying on behalf of the Federal Trade Commission before the U.S. Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, Chairwoman Edith Ramirez outlined how effective antitrust enforcement benefits both consumers and businesses by preventing mergers and business conduct that could lead to higher prices, lower quality products and services, and less innovation.
Citing the US Supreme Court’s recent decision in North Carolina State Board of Dental Examiners v. FTC, Chairwoman Ramirez noted that “[f]ederal antitrust law is a central safeguard for the Nation’s free market structures.”
In testimony presented to the subcommittee, the Federal Trade Commission described its current competition enforcement activities and priorities. According to the testimony, during calendar year 2015, the Commission challenged 27 mergers. In most, it negotiated a remedy that preserved competition in the affected markets, allowing the merger to proceed. However, the Commission filed suit to block six transactions.
The six litigated merger challenges include last year’s successful effort to block Sysco’s acquisition of rival US Foods. A federal court agreed with the FTC in ruling that the merger was likely to lessen competition in broadline foodservice distribution markets, both nationwide and in a number of local markets around the country, leading to higher prices and diminished quality.
Four litigations are ongoing, including three seeking to stop anticompetitive hospital mergers – in Huntington, West Virginia, Harrisburg, Pennsylvania, and the North Shore area of Chicago. The other pending suit, FTC v. Staples, Inc., challenges the merger between the two largest sellers of consumable office supplies to large business customers with a preliminary injunction hearing set to begin in federal court in Washington, D.C. later this month.
The testimony also notes that in the last two years alone, the agency has taken action in 17 pharmaceutical industry mergers, ordering divestitures in the sale of dozens of both branded and generic drugs used to treat a variety of conditions, such as hypertension, cirrhosis, and bipolar disorder.
Full Content: Yuma News Now
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Japan’s Prime Minister Criticizes US Block on Nippon Steel-US Steel Deal
Feb 17, 2025 by
CPI
UAE Cabinet Announces New Merger Control Filing Thresholds Effective March 2025
Feb 17, 2025 by
CPI
UK Regulator Warns Topps Tiles Acquisition Could Hurt Competition
Feb 17, 2025 by
CPI
FTC Chair Andrew Ferguson Backs Trump’s Authority to Remove Commissioners
Feb 17, 2025 by
CPI
South Korea Suspends Downloads of Chinese AI App DeepSeek Over Data Privacy Concerns
Feb 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon